Hanyu Pharmaceutical: Glytratrexate Acetate Injection Receives FDA Approval Certificate

Hanyu Pharmaceutical announced that it has recently received the approval certificate for the New Drug Application (NDA) of Glatiramer Acetate Injection from the U.S. Food and Drug Administration (FDA). Glatiramer Acetate is an immunomodulatory drug used to treat relapsing multiple sclerosis (MS). It is a synthetic polypeptide that mimics the structure of myelin basic protein, regulating abnormal autoimmune responses to reduce attacks on the myelin sheath in the central nervous system. This medication can decrease relapse frequency, slow disease progression, and is suitable for patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis.